miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced incremental new data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in adult T-cell leukemia/lymphoma (ATLL) in an oral presentation at the 19th International Congress HTLV 2019, which is being held from April 24 – 26, 2019, in Lima, Peru.
Read MoreORIX Growth Capital completes investment in Zenoss, one of the leading technology companies providing modern monitoring and AI-driven analytics for hybrid and multi-cloud IT environments.
Read MoremiRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2018.
Read MoreCorporate investments in renewable energy used to be symbolic. A few solar panels here, a small wind farm investment there. But in 2018 some companies became voracious green energy consumers.
Read More